Werfen account plan
Specialized diagnostics worldwide leader
At a glance
Werfen is a family-owned Barcelona in-vitro diagnostics group with FY2025 sales of €2.1 billion and 7,131 employees.
Werfen is a family-owned specialized in-vitro diagnostics (IVD) group founded in 1966 in Barcelona. It develops, manufactures and distributes instruments, reagents and data management solutions in Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity and Transplant for hospitals, hospital networks, commercial and reference laboratories and blood donor centers. It has direct operations in 30 countries, distributors in more than 100 territories and 7,131 employees at year-end 2025. FY2025 sales were €2,131M (+3.3% at constant exchange rate and perimeter) with EBITDA of €473M (22% margin); 95% of revenue is recurring, on an installed base of 99,895 active instruments.
Business units
Hemostasis
33% of 2025 sales (€699M)Systems, reagents and data management for diagnosing bleeding and thrombotic disorders, including the ACL TOP Family and HemosIL assays. Sales declined 0.8% globally in 2025 but grew 4.5% excluding China. Led by Giovanni Russi, Chief Operating Officer, Hemostasis and Acute Care Diagnostics.
Acute Care Diagnostics
30% of 2025 sales (€649M)Point-of-care Blood Gas, Whole Blood Hemostasis and Patient Blood Management systems such as GEM Premier and ROTEM. Global sales grew 4.7% (8.6% excluding China), with the GEM Premier 7000 with iQM3 expanding from the US into Europe, Oceania and Japan. Also led by Giovanni Russi.
Transfusion
13% of 2025 sales (€276M)Immunohematology reagents, automated blood bank instruments, molecular immunohematology and ImmuLINK data management for hospitals, reference labs and blood donor centers. It made 206 new installs in 2025 and has over 85% of its portfolio IVDR-certified. Led by Dominique Petitgenet, Chief Operating Officer, Transfusion.
Autoimmunity
9% of 2025 sales (€192M)Reagents and systems for connective tissue diseases, rheumatoid arthritis, vasculitis and celiac disease, including Aptiva and BIO-FLASH. Sales grew 8% in 2025, with double-digit growth in North America, Latin America, the UK and Oceania. Led by Vijay Namasivayam, Chief Operating Officer, Autoimmunity.
Transplant
3% of 2025 sales (€66M)Pre- and post-transplant HLA diagnostics, including LIFECODES assays, MatchX analytics and NGS products from Omixon. Sales grew 10.8% globally in 2025. Led by Jordi Llorens, Chief Operating Officer Transplant since January 2026.
Other Businesses
12% of 2025 salesThe Barcelona Immunoassay Technology Center (hemostasis immunoassays, autoimmunity biomaterials and OEM products for other IVD companies), Clinical Chemistry and Toxicology, and distribution of partners' specialized diagnostic products mainly in Spain, Portugal and Mexico. It includes the Werfen-Seegene molecular diagnostics joint venture.
Strategic priorities
- 3-Year Strategic Plan 2025-2027
- 2025 was year one of "Solidifying for Growth", which strengthens mission-critical functions (cybersecurity, compliance, quality and regulatory), facilities and talent. The CEO's target is to be stronger in organization, innovation and financial strength by the end of 2027.
- Digital as a third pillar
- In 2026 the CEO wants Digital to stand alongside instruments and reagents. Digital Solutions built a production-ready cloud foundation for future SaaS offerings and obtained Spain's ENS cybersecurity certification.
- Project CODE
- A single Commercial Operations Digital Ecosystem that integrates sales, marketing, service and applications.
- Deleveraging
- The CFO's primary commitment for 2026 is to continue deleveraging and keep ample operating liquidity; Net Debt-to-EBITDA rose to 3.5x in 2025 from 3.0x.
- North America large accounts
- In 2026 North America will target large health systems, reference labs, GPOs and donor centers. The region is the largest at 37% of sales (€790M, +8%) and created an Automation and IT Solutions division.
Latest results
Werfen's latest published figures are for FY2025 (released 9 April 2026); no H1 2026 report is public. Sales were €2,131M, up 3.3% at constant exchange rate and perimeter, and up 6% excluding China, with North America +8%, Latin America +10% and EEMEA +7%. EBITDA fell to €473M (22% margin) from €545M (25%) in 2024, which the CFO called a year of adjustment. Net debt was €1,661M vs €1,617M, and a €500 million bond extended maturities while the Investment Grade rating was kept. No numeric guidance is given; the CFO expects 2026 to remain challenging.
Investments and deals
- R&D
- Record R&D investment of €190M in 2025 (9% of sales, +8% vs 2024), with 900+ R&D employees; launches include the ACL TOP Family 70 Series and the GEM Premier 7000 with iQM3.
- US facilities
- A new North America Distribution Center in Devens, MA (more than 230,000 sq. ft.), the acquired 130,536 sq. ft. San Diego Whole Blood Hemostasis Technology Center, and nearly 10,000 m² of added R&D and manufacturing space in Bedford.
- Werfen-Seegene joint venture
- A joint venture with Seegene to develop and manufacture molecular diagnostics at the Lliçà d'Amunt site.
- Portfolio moves
- Immucor (2023) created the Transfusion and Transplant lines, Omixon was acquired in 2024, and the Medical Devices distribution business was divested in July 2024.
Challenges and risks
- China market correction
- Diagnostic stewardship and reimbursement policy in China cut prices and volumes; China sales (€187M) fell vs 2024.
- Margin and leverage
- EBITDA margin fell to 22% from 25% and Net Debt-to-EBITDA rose to 3.5x from 3.0x.
- Tariffs and currency
- Trade tensions, higher tariff costs and unfavorable foreign exchange weighed on 2025.
- European lab budgets
- Europe grew 3.6% amid fiercely competitive conditions and tighter lab spending.
- Regulation and cybersecurity
- IVDR, software-as-a-medical-device regulation, product cybersecurity and software obsolescence are named risks.
What leadership says
“We haven't hit the brakes on our plans; on the contrary, we have continued to invest with a forward-looking vision.”
“Our capital structure is exceptionally resilient.”
“Looking to 2026, we expect continued global turbulence”
“By the end of 2027, we will be a stronger company in terms of our organization, innovation and financial strength”
Where a supplier can help
- Commercial platform for Project CODE
- Unifying sales, marketing, service and applications into one digital ecosystem opens room for CRM, service-management and data-integration suppliers.
- Cloud, SaaS and cybersecurity
- The Digital third pillar, the cloud foundation for SaaS offerings and new leadership in cybersecurity point to needs in cloud engineering, security and software-as-a-medical-device compliance tooling.
- Cost and cash discipline
- With leverage at 3.5x and deleveraging the 2026 priority, offers that lower operating cost or improve cash generation fit the CFO's agenda better than new spend.
- Logistics and facilities in the US
- The Devens distribution center, San Diego site and Bedford expansion create needs in warehouse operations, cold-chain and facility services.
- Compliance and quality systems
- New Chief Compliance Officer and Global Risk Officer roles plus IVDR work suggest demand for compliance, quality and regulatory tooling.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Werfen?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Werfen Annual Review 2025
- Werfen is a family-owned specialized in-vitro diagnostics (IVD) group founded in 1966 in Barcelona, active in Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity and Transplant; direct operations in 30 countries, distributors in more than 100 territories, 7,131 employees.
- FY2025 sales of €2.1 billion (€2,131M), +3.3% at constant exchange rate and perimeter; 95% of revenue is recurring; installed base of 99,895 active instruments.
- Profitability and leverage weakened: EBITDA €473M (22% margin) vs €545M (25%) in 2024; net debt €1,661M vs €1,617M; Net Debt-to-EBITDA up to 3.5x from 3.0x. A bond issue in June extended debt maturities.
- Mix: Hemostasis 33% (€699M), Acute Care Dx 30% (€649M), Transfusion 13% (€276M), Other Businesses 12%, Autoimmunity 9% (€192M), Transplant 3% (€66M). North America is the largest region at 37% (€790M, +8%), Europe 31% (€657M, +3.6%).
- China was the main drag: a market correction linked to diagnostic stewardship and reimbursement policy cut prices and volumes; China sales (€187M) fell vs 2024, Hemostasis declined 0.8% globally but grew 4.5% excluding China. Tariffs and FX also weighed.
- Record R&D investment of €190M (9% of sales, +8% vs 2024), 900+ R&D employees; key rollouts are the ACL TOP Family 70 Series (hemostasis) and GEM Premier 7000 with iQM3 (first point-of-care blood gas analyzer with hemolysis detection).
- Strategy: 3-Year Strategic Plan 2025-2027 "Solidifying for Growth" - strengthening mission-critical functions (cybersecurity, compliance, quality/regulatory), facilities (new Devens, MA distribution center; San Diego site acquired; Bedford expansion), and project CODE to unify sales, marketing, service and applications in one Commercial Operations Digital Ecosystem.
- CEO Alejandro Risso (joined January 2025) wants to make Digital a third pillar of innovation alongside instruments and reagents in 2026; the chairman Marc Rubiralta expects "continued global turbulence" in 2026 and more weight on local and regional strategies.
- For sellers: North America will target large health systems, reference labs, GPOs and donor centers; new leaders hired in cybersecurity, compliance, quality/regulatory, a Chief Compliance Officer and a Global Risk Officer; cloud foundation built for future SaaS offerings.
- Werfen reaches €2.1 billion in sales and bolsters operational resilience (FY2025 results release)
- Werfen reported FY2025 sales of €2.131 billion with 3.3% organic growth, published 9 April 2026.
- Excluding the temporary effect of China ("the Asian market"), organic sales grew 6%: North America +8%, Latin America +10%, EEMEA +7%.
- EBITDA of €473 million; net financial debt of €1.661 billion, described as stable year over year.
- R&D investment of €190 million, 9% of net sales; Bedford (USA) technology center expanded by nearly 10,000 m² of R&D and manufacturing space; move to a new logistics hub in Devens (USA) finalized.
- After the July 2024 divestment of the non-strategic Medical Devices business, 2025 figures are In-Vitro Diagnostics only.
- A €500 million bond extended maturities; Werfen keeps its Investment Grade credit rating.
- CFO Javier Gómez: the "primary commitment for 2026 is to continue deleveraging and maintaining ample operating liquidity".
- CEO Alejandro Risso: "We haven't hit the brakes on our plans; on the contrary, we have continued to invest with a forward-looking vision."
- CEO Interview: Carlos Pascual and Alejandro Risso (Werfen Annual Review 2024, pp. 8-9)
- Annual Review 2024 interview (published April 2025) with outgoing CEO Carlos Pascual and incoming CEO Alejandro Risso, conducted by Senior Director of Global Communications Nicky Salas.
- Pascual: 2024 diagnostics sales grew 6% at constant exchange rate and perimeter, the sales budget was exceeded across all geographies and most business units, and operating income increased.
- The 2022-2024 strategic plan met its eight main objectives, including the sales and operating income targets; it included Werfen's biggest acquisition, Immucor, and the integration of the Transfusion and Transplant business lines.
- The Omixon acquisition was made because "the future of Transplant diagnostics is Next Generation Sequencing".
- Pascual stepped down after 37 years at the company, 12 of them as CEO; Risso took over on May 1, 2025.
- Risso came from Thermo Fisher Scientific, where he was President of Clinical Diagnostics, and has worked in family-owned, publicly traded and consulting companies.
- The 2025-2027 plan focuses on core strengths, enhancing the organization and the specialization strategy. Risso's target: "By the end of 2027, we will be a stronger company in terms of our organization, innovation and financial strength".
- Risso sees long-term vision and focus on specialized diagnostics as the advantages of family ownership.
Questions about Werfen
What does Werfen do?
Werfen develops, manufactures and distributes in-vitro diagnostic instruments, reagents and data management solutions in Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity and Transplant, for hospitals, laboratories and blood donor centers.
What is Werfen's revenue?
FY2025 sales were €2,131M, up 3.3% at constant exchange rate and perimeter, with EBITDA of €473M.
How many employees does Werfen have?
Werfen had 7,131 employees at year-end 2025, with direct operations in 30 countries.
Who leads Werfen?
Alejandro Risso, formerly President of Clinical Diagnostics at Thermo Fisher Scientific, is CEO; Marc Rubiralta chairs the board and Javier Gómez is CFO. Werfen is family-owned.
What is Werfen's strategy?
The 2025-2027 plan "Solidifying for Growth" strengthens the organization, specialization and digital, while the 2026 financial priority is deleveraging.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)